US Edition
Boston Scientific’s Agent DCB Granted NTAP From CMS - Cardiac Interventions Today
Summary by Cardiac Interventions Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Boston Scientific’s Agent DCB Granted NTAP From CMS - Cardiac Interventions Today
August 4, 2025—Boston Scientific recently announced that the US Centers for Medicare & Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the company’s Agent drug-coated balloon (DCB). Beginning October 1, 2025, CMS will provide hospitals with additional device reimbursement when the Agent DCB is used for eligible cases in the hospital inpatient setting, advised the company. The Agent DCB received FDA approval in the Unit…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
